Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)

Exclusion Criteria

• •1. Have indication for dapagliflozin;
• •2. Angioedema, or allergic to dapagliflozin;
• •3. Already taking Dapagliflozin or other SGLT2 inhibitors;
• •4. Primary mitral valve structural damage, such as rheumatic heart disease, mitral valve prolapse;
• •5. Non-dialysis patients with estimated glomerular filtration rate\<30ml/min/1.73m2;
• •6. Dialysis patients;
• •7. Acute myocardial infarction, acute myocarditis, or percutaneous transluminal coronary intervention, coronary artery bypass grafting and other vascular reconstruction operations have occurred within 3 months;
• •8. Those who plan to take vascular reconstruction, cardiac resynchronization therapy, percutaneous mitral valve repair, surgical valve repair or replacement within 3 months after enrollment;
• •9. Complications of obvious aortic valve disease (more than moderate stenosis or more than moderate regurgitation);
• •10. Thyroid function combined with hyperthyroidism has not returned to normal;
• •11. Pregnant and lactating women.